All Stories

Fierce Pharma Asia—Akeso bispecific's first survival readout; AstraZeneca's China probes; Ono's layoffs

Akeso's first overall survival readout for its Keytruda challenger caused a violent market reaction. AstraZeneca disclosed another potential fine in China. Ono unveiled layoffs in a notice filed in Massachusetts. And more.

May 2, 2025 - 13:06
 0
Fierce Pharma Asia—Akeso bispecific's first survival readout; AstraZeneca's China probes; Ono's layoffs
Akeso's first overall survival readout for its Keytruda challenger caused a violent market reaction. AstraZeneca disclosed another potential fine in China. Ono unveiled layoffs in a notice filed in Massachusetts. And more.
Read More

Tags:

Previous Article

Mercedes-Benz enters LiDAR partnership with Luminar

Next Article

Human medicines European public assessment report (EPAR): Lyrica, pregabalin, Da...

Related Posts

Lupin recalls nearly 3,000 bottles of OCD medication in the US after subpar stability testing results

Lupin recalls nearly 3,000 bottles of OCD medication in...

Apr 24, 2025  0

Moderna targets more cost cuts amid broader vaccine market uncertainty under HHS secretary RFK Jr.

Moderna targets more cost cuts amid broader vaccine mar...

May 1, 2025  0

FDA puts up placebo testing requirement for new vaccines, potentially hitting COVID shot makers the hardest: reports

FDA puts up placebo testing requirement for new vaccine...

May 1, 2025  0